AHA names Barbara Riegel, PhD, FAHA, FAAN, a 2015 Distinguished Scientist

November 09, 2015

PHILADELPHIA, PA (November 9, 2015) - The American Heart Association (AHA) has named Penn Nursing's Barbara Riegel, PhD, FAHA, FAAN, professor of Nursing, the Edith Clemmer Steinbright Chair of Gerontology and director of the Biobehavioral Research Center, a 2015 Distinguished Scientist. Riegel received this honor during the opening meeting of the AHA Scientific Sessions on November 8, 2015.

The AHA's Distinguished Scientists are a prominent group of scientists and clinicians whose work has importantly advanced the understanding of cardiovascular diseases and stroke. It honors significant, original and sustained scientific contributions that have advanced the association's mission of "building healthier lives, free of cardiovascular diseases and stroke."

Riegel is an established nurse scientist studying adults with cardiovascular disease. Her primary research interest is self-care of older adults with chronic heart failure. Recently her interests have expanded to include multimorbidity--a common phenomenon in adults with heart failure. She focuses her research on the self-care issues of medication adherence and decision-making in response to symptoms. Her finding have demonstrated that poor medication adherence is a primary contributor to hospitalization in heart failure, identified intentional and unintentional factors associated with poor medication adherence, and developed an approach to improving medication adherence in these patients.

Riegel has more than 250 peer-reviewed publications and is often invited to speak nationally and internationally on self-care. This interest grew out of her early years as a clinical nurse researcher in California, where she led several studies testing disease management approaches to transitioning chronically ill patients from hospital to home, a theme that continues in her current program of research.

This is the third major honor Riegel has received this year. Earlier in 2015 she was inducted into the Sigma Theta Tau International Nurse Researcher Hall of Fame, and presented the AHA Council on Cardiovascular and Stroke Nursing's Kathleen A. Dracup Distinguished Lecture in Exemplary Early-Career Mentoring.
-end-
About the University of Pennsylvania School of Nursing

The University Of Pennsylvania School Of Nursing is one of the world's leading schools of nursing and is ranked the #1 graduate nursing school in the United States by U.S. News & World Report. Penn Nursing is consistently among the nation's top recipients of nursing research funding from the National Institutes of Health. Penn Nursing prepares nurse scientists and nurse leaders to meet the health needs of a global society through research, education, and practice.

University of Pennsylvania School of Nursing

Related Heart Failure Articles from Brightsurf:

Top Science Tip Sheet on heart failure, heart muscle cells, heart attack and atrial fibrillation results
Newly discovered pathway may have potential for treating heart failure - New research model helps predict heart muscle cells' impact on heart function after injury - New mass spectrometry approach generates libraries of glycans in human heart tissue - Understanding heart damage after heart attack and treatment may provide clues for prevention - Understanding atrial fibrillation's effects on heart cells may help find treatments - New research may lead to therapy for heart failure caused by ICI cancer medication

Machining the heart: New predictor for helping to beat chronic heart failure
Researchers from Kanazawa University have used machine learning to predict which classes of chronic heart failure patients are most likely to experience heart failure death, and which are most likely to develop an arrhythmic death or sudden cardiac death.

Heart attacks, heart failure, stroke: COVID-19's dangerous cardiovascular complications
A new guide from emergency medicine doctors details the potentially deadly cardiovascular complications COVID-19 can cause.

Autoimmunity-associated heart dilation tied to heart-failure risk in type 1 diabetes
In people with type 1 diabetes without known cardiovascular disease, the presence of autoantibodies against heart muscle proteins was associated with cardiac magnetic resonance (CMR) imaging evidence of increased volume of the left ventricle (the heart's main pumping chamber), increased muscle mass, and reduced pumping function (ejection fraction), features that are associated with higher risk of failure in the general population

Transcendental Meditation prevents abnormal enlargement of the heart, reduces chronic heart failure
A randomized controlled study recently published in the Hypertension issue of Ethnicity & Disease found the Transcendental Meditation (TM) technique helps prevent abnormal enlargement of the heart compared to health education (HE) controls.

Beta blocker use identified as hospitalization risk factor in 'stiff heart' heart failure
A new study links the use of beta-blockers to heart failure hospitalizations among those with the common 'stiff heart' heart failure subtype.

Type 2 diabetes may affect heart structure and increase complications and death among heart failure patients of Asian ethnicity
The combination of heart failure and Type 2 diabetes can lead to structural changes in the heart, poorer quality of life and increased risk of death, according to a multi-country study in Asia.

Preventive drug therapy may increase right-sided heart failure risk in patients who receive heart devices
Patients treated preemptively with drugs to reduce the risk of right-sided heart failure after heart device implantation may experience the opposite effect and develop heart failure and post-operative bleeding more often than patients not receiving the drugs.

How the enzyme lipoxygenase drives heart failure after heart attacks
Heart failure after a heart attack is a global epidemic leading to heart failure pathology.

Novel heart pump shows superior outcomes in advanced heart failure
Severely ill patients with advanced heart failure who received a novel heart pump -- the HeartMate 3 left ventricular assist device (LVAD) -- suffered significantly fewer strokes, pump-related blood clots and bleeding episodes after two years, compared with similar patients who received an older, more established pump, according to research presented at the American College of Cardiology's 68th Annual Scientific Session.

Read More: Heart Failure News and Heart Failure Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.